Pfizer's new RSV vaccine given to pregnant women to protect their babies shows major promise
Daily MailPfizer has announced its experimental RSV vaccine is highly effective — giving a glimmer of hope for parents and doctors. Administering the vaccine to expectant mothers was shown to be nearly 82 per cent effective at preventing severe illness caused by RSV in infants during their first 90 days of life. RSV cases were also considered severe if the patient's blood oxygen levels fell below 93 per cent, if they required high-flow supplemental oxygen, if they were admitted to the ICU, or if they lost consciousness. Dr Eric Simões, a pediatric infectious diseases expert at the University of Colorado School of Medicine and Children’s Hospital Colorado celebrated the maternal vaccine, saying it could substantially reduce the number of RSV cases currently in hospitals. Professor Jonathan Ball, Professor of Molecular Virology, University of Nottingham in the UK said that past failures to develop a viable RSV vaccine makes Pfizer's news all the more exciting 'The news from Pfizer that their early clinical trial data suggests good protection against lung infection following vaccination of pregnant mothers is great news,’ Prof Ball said.